Hoth Stock Soars On Announcement Of Positive Data For HT-001 In EGFRI-Associated Skin Toxicities

(RTTNews) - Hoth Therapeutics, Inc. (HOTH), Thursday announced promising data from the first human treatment of epidermal growth factor receptor inhibitor or EGFRI-associated papulopustular eruptions with its novel therapeutic HT-001.

During the study, the company reported significant improvement within one week of initiating therapy in a 59-year-old female undergoing treatment for metastatic breast cancer.

The biotechnology company has also initiated a Phase 2a clinical trial to further evaluate the efficacy and safety of HT-001 in the treatment of EGFRI-associated skin toxicities.

Currently, Hoth's stock is trading at $1.32, up 90.04 percent on the Nasdaq.